Wall Street Zen Downgrades Humacyte (NASDAQ:HUMA) to Strong Sell

Humacyte (NASDAQ:HUMA) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

HUMA has been the subject of a number of other reports. BTIG Research decreased their target price on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Benchmark reduced their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and an average target price of $7.71.

Humacyte Stock Up 0.7%

Shares of NASDAQ HUMA opened at $0.65 on Friday. The stock has a market cap of $144.31 million, a PE ratio of -3.25 and a beta of 2.11. The company has a quick ratio of 2.95, a current ratio of 3.69 and a debt-to-equity ratio of 20.08. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.93. The business has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.21.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $1.35 million. Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%. Equities research analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Hedge Funds Weigh In On Humacyte

A number of large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its stake in shares of Humacyte by 841.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after buying an additional 62,931 shares in the last quarter. Aristides Capital LLC purchased a new position in shares of Humacyte during the 4th quarter worth approximately $156,000. Virtu Financial LLC purchased a new position in shares of Humacyte during the 4th quarter worth approximately $252,000. XTX Topco Ltd increased its holdings in shares of Humacyte by 236.1% in the 4th quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock valued at $625,000 after purchasing an additional 457,236 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Humacyte in the 4th quarter valued at about $201,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.